FDA lifts clinical hold on trial of Celyad Oncology’s CAR T-cell therapy

The FDA lifted its clinical hold on a trial designed to evaluate CYAD-101, an investigational chimeric antigen receptor T-cell therapy.
The international, multicenter phase 1B KEYNOTE-B79 trial is designed to evaluate CYAD-101 (Celyad Oncology) — an allogeneic, NKG2D-directed CAR T-cell therapy — with concurrent FOLFOX chemotherapy followed by pembrolizumab (Keytruda, Merck) for patients with treatment-refractory metastatic colorectal cancer.
Celyad Oncology placed a voluntary pause on the trial in late February after two patients treated with the agent died. The company halted

The FDA lifted its clinical hold on a trial designed to evaluate CYAD-101, an investigational chimeric antigen receptor T-cell therapy.
The international, multicenter phase 1B KEYNOTE-B79 trial is designed to evaluate CYAD-101 (Celyad Oncology) — an allogeneic, NKG2D-directed CAR T-cell therapy — with concurrent FOLFOX chemotherapy followed by pembrolizumab (Keytruda, Merck) for patients with treatment-refractory metastatic colorectal cancer.
Celyad Oncology placed a voluntary pause on the trial in late February after two patients treated with the agent died. The company halted